Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis

Randomized Placebo-controlled Trial of the Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis.

This prospective placebo-controlled trial will enroll 20 patients with SSc and at least one calcinotic lesion of the hands that is palpable on physical examination and measurable on hand radiographs. Each subject will undergo a screening evaluation 1 month before treatment with the study drug is initiated. Each subject will be instructed to blindly self-apply either topical 25% sodium metabisulfite or placebo cream twice daily. In-person follow-up evaluations will be performed after 4-months, with monthly telehealth follow-up visits to ensure adherence and arrange study drug refill deliveries.

1. Background:

   Calcinosis cutis is the deposition of calcium in the skin and subcutaneous tissues. It is a common and debilitating manifestation of systemic sclerosis (SSc), affecting 1 in 4 of these patients over the course of their disease. Calcinosis in SSc occurs most frequently in the hands, particularly the fingers, and within the fingers, most commonly in the thumbs or index of the dominant hand. Calcinosis in SSc can cause pain, soft tissue swelling around the calcium deposits, ulcers with superimposed infection, or deformities, leading to significant impact on quality of life.

   Treatment for calcinosis cutis is often difficult and unsuccessful and remains an unmet need in patients with SSc. Evidence mainly comes from small retrospective studies, case series, and case reports, since no large, prospective randomized controlled trials have been conducted. The response to various agents, such as topical or oral aluminum hydroxide, topical or intralesional sodium thiosulfate, intralesional corticosteroids, calcium-channel blockers, minocycline, bisphosphonates, and surgical excision has remained largely unsatisfactory.

   Topical, intralesional and intravenous (IV) sodium thiosulfate have been studied as treatments for disorders of cutaneous calcium deposition. The mechanism of sodium thiosulfate in the treatment of calcium-related disorders is thought to be multifactorial. It is believed to act by transforming calcium into calcium thiosulfate salts, thus increasing calcium solubility. In addition, it may increase the production of hydrogen sulfide, which has vasodilatory, antioxidant and anti-inflammatory properties, and may cause direct inhibition of vascular calcifications.

   Sodium metabisulfite (SM) is an inorganic compound used as a disinfectant, antioxidant and preserving agent that, when reacting with oxygen, becomes sodium sulfate, a metabolite of sodium thiosulfate that has a similar ability to inhibit calcium oxalate agglomeration and calcium stone formation. In 2016, topical 25% SM was used for the first time in four patients with dystrophic calcinosis cutis (one with SSc, two with dermatomyositis and one with radio-dermatitis after breast cancer), showing significant decrease in size, erythema, and pain. The authors hypothesized that topical SM may dissolve calcium deposits and promote local vasodilation and wound healing. Since then, topical sodium metabisulfite use has been reported as an inexpensive, safe and promising new agent for the treatment of calcinosis cutis.

   On behalf of the Scleroderma Clinical Trial Consortium (SCTC) Calcinosis Working Group, we developed and validated a novel radiographic scoring system to assess the severity of calcinosis affecting the hands of patients with SSc that accounts for area coverage, density, and anatomic location. This scoring system is feasible and was found to have excellent intra- and inter-rater reliability with intra-class correlation coefficients (ICC) of .93 (.89-.97) and .89 (.86-.92), respectively. We confirmed the excellent inter-rater reliability of our radiographic calcinosis scoring system and demonstrated its usefulness to detect change over time in a recent study of 39 patients and a validation cohort of 19 patients.Calcinosis in SSc usually progresses over time. In this same study, 80% of patients had worsening or unchanged calcinosis without treatment at 1 year follow-up as measured by this radiologic scoring system.

   Given that calcinosis is a frequent, debilitating, and progressive complication of SSc with no effective therapies, a clinical trial, using novel outcome measures, testing the safety and efficacy of a potential treatment of calcinosis is warranted.

2. Primary/Secondary objectives:

   Our main objective is to conduct a study with the following primary and secondary endpoints.

   Primary endpoints:

   • To assess the safety and tolerability of using topical 25% SM applied twice daily in SSc patients with calcinosis affecting the hands.
   • To assess the efficacy of topical 25% SM versus placebo in stabilizing the calcinosis burden or reducing the radiographic progression of calcinosis over four months.

   Secondary endpoints:

   • To assess the effect of topical 25% SM on the change in the Mawdsley Calcinosis Questionnaire, and patient and physician assessment of calcinosis severity over four months.
   • To assess the effect of topical 25% SM on the change in size of calcinosis on ultrasound.

   To assess the presence of markers of vascular damage by tape stripping in SSc patients with calcinosis.

3. Hypothesis:

   We hypothesize that topical SM may be beneficial in the treatment of calcinosis in patients with SSc stabilizing the burden of calcinosis as measured by the SCTC radiologic scoring system.

4. Study design:

   This prospective placebo-controlled trial will enroll 20 patients with SSc and at least one calcinotic lesion of the hands that is palpable on physical examination and measurable on hand radiographs. Each subject will undergo a screening evaluation 1 month before treatment with the study drug is initiated. Each subject will be instructed to blindly self-apply either topical 25% SM or placebo cream twice daily. Follow-up in-person evaluations will be performed a 4-month period, with monthly telehealth follow-up visits to ensure adherence and provide study drug.

5. Study population:

   The population for this study will consist of adult SSc patients with evidence of at least one calcinotic lesion of the hands that is palpable on physical examination and measurable on hand radiographs. Inclusion and exclusion criteria have been entered elsewhere.

6. Description of the treatment:

   Each subject will be randomized and instructed to blindly self-apply, either SM prepared in pediatric cold cream (water in oil emulsion) at a concentration of 25% or placebo topically twice daily, which will be continued as tolerated. Vinyl gloves will be supplied to each patient to improve topical absorption. Patients will participate in a learning session with examples and instructions on how to use the cream. Detailed instructions will be provided to patients for their reference during treatment.

7. Description of Assessments:

   Medical history including SSc: Significant past or present illnesses, current prescription, or nonprescription medications (including vitamins and herbal products), and history of allergies or idiosyncratic responses to drugs will be noted at the time of enrolment. Demographic and clinical data, including age, gender, race, smoking status, disease duration defined from onset of RP and from first non-RP symptom, SSc skin subtype, internal organ involvement, and auto-antibodies including SSc-specific and anti-phospholipid antibodies will be recorded.

   Physical examination: A complete physical examination will be conducted by a physician at screening, baseline and at end of study.

   Vital Signs: Systolic and diastolic blood pressure, heart rate, and temperature (°C) will be measured after sitting for 5 minutes at screening, baseline, and 4 months. Vital signs should also be assessed in the case of abnormal clinical signs and symptoms.

   Laboratory tests: Blood and urine samples for the measurement and evaluation of routine blood laboratory test CBC, CMP, and pregnancy urine test for fertile women will be collected at screening and at the end of the study.

   Tape stripping: Skin samples will be obtained using the tape stripping technique, utilizing five standard D-Squame® sampling discs (Cuderm, Dallas, USA) at the same site on the hands before the initiation of topical treatment with SM or a placebo and at the conclusion.

   Radiological examination of calcinosis: Descripcion has been entered elsewhere

   Ultrasonography (US): Descripcion has been entered elsewhere.

   Mawdsley Calcinosis Questionnaire (MCQ): Descripcion has been entered elsewhere.

   Patient and Physician global assessments: Descripcion has been entered elsewhere.

8. Safety monitoring and reporting Safety: During the study, the primary assessment of safety will be the development of adverse events.

   Adverse Event (AE): An AE is any untoward medical experience occurring to a subject during a clinical trial whether it is related to the study drug. An AE may include an intercurrent illness, injury, or any other concomitant impairment of the subject's health, as well as abnormal laboratory findings if deemed to have clinical significance. AEs may also include worsening of an existing symptom or condition or post-treatment events that occur because of protocol-mandated procedures.

   Severe Adverse Event (SAE): A SAE is an AE occurring at any dose that results in any of the following outcomes:

   • Death
   • A life-threatening AE
   • Inpatient hospitalization or prolongation of existing hospitalization
   • A persistent or significant disability / incapacity
   • A congenital anomaly / birth defect

   In addition, important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the subject and require medical / surgical intervention to prevent one of the outcomes listed above.

9. Statistical Considerations:

   Statistical analysis:

   Descriptive statistics and frequency distributions of all variables of interest will be reported as proportions (%) for categorical variables and as mean ± standard deviation or median (range) for continuous variables. Baseline to 4-month differences and 95% confidence intervals will be calculated for scored outcomes (x-ray score, physician's global assessment by VAS, and quality of life measurements). For the primary efficacy endpoint, mean change and standard deviation in calcinosis burden assessed by radiograph from baseline to 4-month visit, we will use Student's t-test. The mean rate of change of calcinosis in radiograph will be calculated with the following formula: (Year 1 XR score - Baseline XR score)/time. XR score is defined as: sum of scores for 22 weighted areas affecting each hand: %area coverage (0-100) X density (1-3) X weight for each area.(19)

   Sample size calculation:

   We are planning a study of a continuous response variable from independent control and experimental subjects with 1 control(s) per experimental subject. In a previous study the response within each subject group was normally distributed with standard deviation 3,2. If the true difference in the experimental and control means is 4,2, we will need to study 10 experimental subjects and 10 control subjects to be able to reject the null hypothesis that the population means of the experimental and control groups are equal with probability (power) 0,8. The Type I error probability associated with this test of this null hypothesis is 0,05.

10. Risks of Treatment The main risks of the treatment are the same as those secondary to the use of any other cream or topical treatment; participants may experience burning, pain, or allergies in the treatment area. In case of any of these adverse effects, the participant will be evaluated by a Dermatologist member of our team.

However, in a 2022 review in which the best scientific evidence of all published works that included the use of sodium metabisulfite cream for the treatment of skin calcifications in autoimmune patients was analyzed, out of a total of 7 patients, none of them presented any adverse effect with the application of said cream, so with the current evidence to date, the probability of presenting any adverse effect from the use of this topical treatment is very low, that is, less than 0.1% or less than 1 person in every 1000 people who use this cream.

Inclusion Criteria:

• Signed written informed consent
• Age > 18 years of age
• Diagnosis of limited or diffuse cutaneous systemic sclerosis (SSc) according to the revised 2013 ACR/EULAR classification criteria for SSc (21)
• Radiological and physical examination evidence of at least one subcutaneous calcium deposition in the hands that is clinically apparent as part of routine clinical care.
• If female of childbearing potential, the patient must have a negative pregnancy test at screening and baseline visits
• Oral corticosteroids (≤ 5 mg/day of prednisone or equivalent) and NSAIDs are permitted if the patient is on a stable dose regimen for ≥ 2 weeks prior to screening and throughout the study
• Oral CCB, alpha-1-antagonists, ACE-inhibitors, angiotensin receptor blockers, and protein-pump inhibitors are permitted if the doses are stable for 4 weeks prior to screening and throughout the study.

Exclusion Criteria:

• Rheumatic disease other than SSc
• Allergy to sodium metabisulfite
• Pregnant or nursing women
• Concurrent malignancy except non-melanoma skin cancers
• Patients receiving bisphosphonates, warfarin, colchicine, minocycline, intravenous immunoglobulins, or biological agents specifically abatacept or rituximab within 4 weeks of screening
• Patients receiving local treatments for calcinosis of the hands including surgical removal or intralesional steroid injections within 12 weeks of screening or throughout the study.
• Patients who have participated in another clinical trial of an investigative agent within 30 days of screening (or 5 half-lives of the investigational drug, whichever is longer)
• Patients with a history of drug or alcohol abuse within 6 months of screening
• Any medical condition that, in the opinion of the investigator, might interfere with the subject's participation in the study or poses an added risk for the subject
• Inability to comply with study and follow-up procedures